Physician profile
Florin D Andreca
NPI 1700854239
$5,051.49
in general payments reported to CMS, 2019-2025
38 companies · $2,388 in 2025
The $2,388 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.77 · 2020: $11.82 · 2021: $356 · 2022: $495 · 2023: $203 · 2024: $1,577 · 2025: $2,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160 · Education: $6.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,159.83 |
| Education | $6.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.18 | 2022-2025 | Lynparza, Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $531.17 | 2022-2025 | Opdivo, Opdualag, Breyanzi |
| Merck Sharp & Dohme LLC | $347.26 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $342.41 | 2020-2022 | |
| Pfizer INC. | $311.62 | 2019-2025 | |
| Eisai INC. | $300.30 | 2022-2024 | |
| Genentech USA, INC. | $229.82 | 2024-2025 | Tecentriq, Polivy, Phesgo |
| Pharmaessentia USA Corporation | $203.18 | 2025 | Besremi |
| Abbvie INC. | $202.64 | 2024-2025 | |
| Beigene USA, INC. | $196.06 | 2024-2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $155.37 | 2024-2025 | Fruzaqla |
| Incyte Corporation | $148.35 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Array Biopharma INC | $146.99 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $136.45 | 2024-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $132.87 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $127.48 | 2024-2025 | Erleada, Carvykti, Akeega |
| Puma Biotechnology, INC. | $99.87 | 2024-2025 | |
| Stemline Therapeutics INC. | $89.43 | 2024-2025 | Orserdu |
| Seagen INC. | $88.30 | 2023 | Adcetris |
| Pharmacosmos Therapeutics INC. | $65.23 | 2024-2025 | Cosela, Monoferric |
| Celgene Corporation | $58.26 | 2024-2025 | Reblozyl |
| Blueprint Medicines Corporation | $53.82 | 2024-2025 | Ayvakit |
| Caris Mpi, INC. | $52.76 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $46.48 | 2024 | |
| Sobi, INC | $42.92 | 2024 | |
| Tersera Therapeutics LLC | $42.33 | 2024-2025 | Zoladex |
| Coherus Oncology, INC. | $41.55 | 2024-2025 | Loqtorzi |
| Genzyme Corporation | $32.89 | 2025 | |
| Astellas Pharma US INC | $25.66 | 2025 | Padcev |
| Beone Medicines USA, INC. | $22.59 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $19.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.58 | 2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.83 | 2021 | |
| Lilly USA, LLC | $15.61 | 2024 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $14.39 | 2025 | Jemperli, Zejula |
| Azurity Pharmaceuticals, INC. | $13.59 | 2025 | Danziten, Vivimusta |
| Foundation Medicine, INC. | $12.27 | 2021 | |
| Boston Scientific Corporation | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florin Andreca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.